CD‐20 expression in post‐transplant lymphoproliferative disorders: Treatment with Rituximab

B‐cell lymphoproliferative disorders are rare but serious complications of solid organ and bone marrow transplantation. We report that these tumors frequently express the CD‐20 antigen, and immunotherapy directed at this antigen may be a well‐tolerated and effective treatment. Am. J. Hematol. 65:171...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of hematology 2000-10, Vol.65 (2), p.171-173
Hauptverfasser:	Ifthikharuddin, J.J., Mieles, L.A., Rosenblatt, J.D., Ryan, C.K., Sahasrabudhe, D.M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Murine-Derived Antigens, CD20 - blood Antineoplastic agents Biological and medical sciences CD‐20 Child Female Herpesvirus 4, Human - genetics Humans Immunotherapy Infant Intestine, Small - transplantation Liver Transplantation - adverse effects Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - etiology Lymphoma, Large B-Cell, Diffuse - virology Lymphoproliferative Disorders - drug therapy Lymphoproliferative Disorders - etiology Lymphoproliferative Disorders - virology Male Medical sciences Middle Aged Organ Transplantation - adverse effects Pharmacology. Drug treatments Postoperative Complications - drug therapy Postoperative Complications - etiology post‐transplant lymphoproliferative disorder PTLD Rituximab RNA, Messenger - blood Time Factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	B‐cell lymphoproliferative disorders are rare but serious complications of solid organ and bone marrow transplantation. We report that these tumors frequently express the CD‐20 antigen, and immunotherapy directed at this antigen may be a well‐tolerated and effective treatment. Am. J. Hematol. 65:171–173, 2000. © 2000 Wiley‐Liss, Inc.
ISSN:	0361-8609 1096-8652
DOI:	10.1002/1096-8652(200010)65:2<171::AID-AJH14>3.0.CO;2-Z